Immunology Flashcards

1
Q

What are the main APC’s?

A
APCs are cells that express MHC class II
the main APCs that link the innate and adaptive immune systems are:

Dendritic cell
antigen presentation is the main role of these cells
critical in initiation of most adaptive immune response by presenting antigen to lymphocytes

Macrophage
important phagocytes, particularly involved in control of intracellular pathogens
also present antigen on MHC II, helping to activate adaptive immune responses

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What are the functions of cd4+ and cd8+ T cells?

A

CD4+
also known as “T helper cells”
after activation  multiply and form numerous daughter “effector cells”  migrate to sites of inflammation/infection via the bloodstream
produce cytokines that direct the immune response
their role is to “help” other cells carry out their functions
e.g. B cells to produce antibody
macrophages to fight intracellular pathogens

CD8+

kill infected cells (“cytotoxic T cells”)
recognise antigen expressed on the cell surface in conjunction with MHC class I (expressed by all cells)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What are important tissues of the immune system?

A

consist of central (primary) lymphoid tissues
where immune cells are produced
consist of bone marrow and thymus
bone marrow is the site of haematopoesis
B cells (along with myeloid cells) produced and develop in the bone marrow
T cells produced in the bone marrow and travel to the thymus for ‘education

peripheral (secondary) lymphoid tissues
where adaptive immune responses are initiated
lymph nodes
spleen
mucosal associated lymphoid tissue
facilitates antigen and lymphocytes to come together, allowing adaptive immune responses
dendritic cells expressing antigen migrate from tissues to secondary lymphoid organs (e.g. lymph nodes) in lymph via lymphatic vessels
naïve lymphocytes circulate through lymph nodes via the bloodstream

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What is the function of Lymph?

A

lymph is essentially extracellular fluid from all tissue, but contains APCs bringing antigen from tissues
drains in a series of (afferent) lymphatic vessels into secondary lymphoid tissues (e.g. lymph nodes)
fluid (lymph) then leaves lymph nodes via efferent lymphatics vessels, which drain into a collecting lymphatic vessel called the thoracic duct
this then drains into the bloodstream via the heart

naïve lymphocytes enter the lymph nodes from the bloodstream
there they sample the environment for antigen presented by APCs
if they encounter their antigen and are activated they divide to form ‘effector’ cells
effector lymphocytes (or naïve cells that have not encountered their antigen) leave lymph nodes via efferent lymphatics
drain into thoracic duct and back into bloodstream
activated ‘effector’ cells then home to inflamed tissues (e.g. sites of infection)
naïve cells home back to lymph nodes again and continue to circulate between lymph nodes and blood until antigen encountered

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What are the warning signs for immunodeficiency?

A
  • The European Society for Immunodeficiencies warning signs for ADULT primary immunodeficiency diseases:
  • Four or more infections requiring antibiotics within one year (otitis, bronchitis, sinusitis, pneumonia)
  • Recurring infections or infection requiring prolonged antibiotic therapy
  • Two or more severe bacterial infections (osteomyelitis, meningitis, septicaemia, cellulitis)
  • Two or more radiologically proven pneumonia within 3 years
  • Infection with unusual localization or unusual pathogen
  • PID in the family
  • Also remember Failure to Thrive in paediatrics
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What are the important questions to cover in an immunological history?

A

Frequency, site and type of pathogen often determines response
Always think of the full differential diagnosis

Details of all previous infections
Site and frequency
Pathogens
Severity
Need for antibiotics
Hospital admissions
Autoimmunity
Malignancy
Immunisation History
Operations (grommets, lobectomies)
Family History
Serious infections
Immunodeficiencies
Autoimmune diseases
Unexplained sudden deaths
Medication history (secondary immunodeficiency)
Lamotrigine can cause a combined immunodeficiency, with viral, fungal and bacterial infections
Phenytoin can cause hypogammaglobulinaemia (reduced immunoglobulins) and enlarged lymph nodes that can look like lymphoma (pseudolymphoma)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

What are the potential features associated with immunodeficiency?

A
Atypical eczema
Chronic diarrhoea
Failure to thrive
Telangiectasia
Hepatosplenomegaly
Endocrinopathy
Chronic osteomyelitis/deep-seated abscesses
Mouth ulceration
Autoimmunity
Family history
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What are the features associated with secondary antibody deficiency?

A
Possible associated features to consider…
Extremes of age
Uraemia
Toxins
Acute & chronic infections
Burns
Myotonic dystrophy
Protein-losing states
Lymphangiectasia
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What are some important examination findings in immunological diseases?

A

Weight and height (FTT)
Structural damage from infections (ears, lungs, sinuses)
Autoimmune features (vitiligo, alopecia, goitre)
Absent tonsils (XLA)
Lymphadenopathy
Hepatosplenomegaly
Other potential diagnostic features (telangectasia, eczema)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

How can Antibody deficiencies present?

A

Recurrent bacterial infection
Main sites are chest, sinuses (i.e. respiratory tract)
Ear and eye infections also common
Recurrent infection eventually causes end organ damage e.g. bronchiectasis
Primarily encapsulated bacteria
E.g Streptococcus pneumoniae (Pneumococcus), Haemophilus, Klebsiella, Pseudomonas etc.
These have polysaccharide capsule that impairs phagocytosis by phagocytes (e.g. neutrophils and macrophages)
Antibodies are produced against polysaccharide antigens in capsule
Binding of antibodies results in ‘opsonisation’, greatly enhancing phagocytosis by phagocytes
Viruses can usually be cleared, but difficulty forming protective immunity can lead to recurrence (e.g. recurrent shingles)

Age at presentation varies by disease

There can also be a number of non-infectious complications
Increased rates of
Autoimmunity (e.g. autoimmune cytopenias / anaemia, endocrine, rheumatological e.g. SLE-like etc.)
Enteropathy (Coeliac-like condition not gluten sensitive, IBD)
Granulomatous inflammation
Sarcoid-like granulomatous lung disease (GLILD)
Lymphoproliferation, hepatosplenomegaly
Malignancy, particularly lymphoma

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What are the causes of antibody deficiency

A
Primary antibody deficiency
Common variable immunodeficiency (CVID)
X-linked agammaglobulinaemia
IgG subclass deficiency
Specific antibody deficiency with normal immunoglobulins
Hyper IgM syndrome (HIGM) – most are really a combined immunodeficiency
Hyper IgE syndrome (HIGE)
(Selective IgA deficiency)

Combined immunodeficieny

Secondary antibody deficiency 
More common than primary
Drugs [cytotoxics, anti-convulsants, anti-rheumatics, Rituximab]
Radiation
Malignancy [CLL, myeloma]
Loss [gut, kidney]
Nutrition [B12]
Metabolic
Infections (HIV, CMV, EBV, Toxoplasma)
Extremes of age / immunosenescence
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

What Investigations can be done for Antibody

A
Full blood count
Haemoglobin & indices
Malabsorption, anaemia of chronic disease
Evidence for marrow failure
Thrombocytopenia
White cell count
Lymphopenia or lymphocytosis
Neutropenia
Blood film
Abnormal cells [smear cells, blasts
Biochemistry
Liver function tests
Albumin for renal or GI loss
Thyroid function
Creatinine & urea [renal disease]
Blood glucose [HbA1c]
Urinary protein excretion [Stick test first]

“Immunoglobulins” and “antibodies” are essentially interchangeable terms
Routine testing involves testing IgG, IgA and IgM (together constitute almost all serum immunogobulin)
Normal range (adults)
IgG 5.8 - 15.4 g/L
IgA 0.64 - 2.97 g/L
IgM 0.24 – 1.9 g/L (male), 0.71 – 1.9 (female)
Age-specific ranges in children

Normal levels do not exclude significant immunodeficiency
If considering hyper-IgE syndrome also need to check total IgE [typically very raised often >50,000 kU/l]

Always have a least two separate measurements of serum immunoglobulins if low.
Low serum immunoglobulins do not always lead to significant infections
Secondary causes of antibody deficiency particularly are often suprisingly well tolerated
Low serum immunoglobulins do not automatically mean that immunoglobulin replacement therapy is required!!

Lymphocyte analysis
Basic panel
CD19 or CD20 [B cells]
CD16/56 [NK Cells]
CD3 [pan-T]
CD4 [Th]
CD8 [Tc]
For CVID, consider markers to identify memory and class-switched memory B cells (low in more severe disease)
CD27, CD19
IgM, IgD
Secondary panel
CD5 vs CD19 [CLL]
Kappa & lambda [clonality]
BTK expression (XLA)
CD40, CD4OL

Other markers absent in rare immunodefiencies, including:
ICOS
Iga, Igb
HLA Class I & II

For CVID, consider following to identify memory B cells and type CVID
CD27, CD19
IgM, IgD

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

How does X-linked Gammaglobulinemia occur and present?What treatment is given?

A

The prototypic primary antibody deficiency
First described in 1952 by Ogden Bruton (sometimes called Bruton’s agammaglobulinaemia)

Defect is loss of function mutation in BTK (Bruton’s tyrosine kinase)
This is involved in signalling of pre B cell receptor and B cell receptor
Absence causes block in maturation at pro-B cell stage
No mature B cells form

Classically leads to:
Total absence of circulating B cells
Absent immunoglobulins (IgG, IgA, IgM)

clinical manifestation

Presents in male children, with infections usually starting in first year of life (when maternal IgG dwindles, so not at birth)
Recurrent upper and lower respiratory tract infections
Encapsulated bacteria, e.g. Strep pneumoniae, Haemophilus influenzae, Staph aureus, Pseudomonas
Invariably develop bronchiectasis, especially if delayed diagnosis
Other bacterial infections e.g. meningitis, osteomyelitis, septic arthritis
Most viral infections can be cleared, but sensitive to enteroviruses, including polio live vaccine strain

Treatment
Immunoglobulin replacement (subcutaneous or intravenous) is essential life-long
Sometimes prophylactic antibiotics are also required
Goal is to prevent end organ damage particularly bronchiectasis
Severe refractory cases can treated curatively with haematopoietic stem cell transplant (HSCT)
No live vaccines

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

How Does CVID present and how is it treated?

A

Relatively common as PIDs go, but still rare (approx. 1 in 25000)
Variable, as in reality it is probably many different genetic defects, with broadly similar phenotype (many identified, many likely yet to be)
Primarily antibody deficiency, particularly low IgG (and IgA)
Can present from childhood (not infancy) until well into adulthood
Diagnosis often delayed many years after first manifestations

Manifestation

Bacterial infections, as with XLA
Autoimmune disease
Enteropathy, Coeliac-like, Malabsorption
Lymphoproliferation
Sarcoid-like granulomatous disease, can affect any organ
Granulomatous lymphocytic interstitial lung disease (GLILD)
Liver disease (nodular regenerative hyperplasia)
Malignancy, especially lymphoma (40 fold increased risk)

Treatment

Immunoglobulin replacement as with XLA
Prophylactic antibiotics
Treatment of complications, e.g. autoimmune disease as appropriate
Some patients with active autoimmune disease or GLILD require immunosuppression, including steroids
Monitoring for malignancy, particularly lymphoma
Small (but increasing) numbers of complex patients treated with HSCT (curative but high mortality risk in adults, especially with comorbidity)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

What are the diagnostic criteria for CVID?

A

At least one of:
Increased susceptibility to infection
Autoimmune manifestations
Granulomatous disease
Unexplained polyclonal lymphoproliferation
Affected family member with Ab deficiency
AND
Marked decreased in IgG and IgA (+/- IgM)
AND at least one of:
Poor vaccine response (or absent isohaemaglutinins)
Low class-switched memory B cells
AND
Secondary causes excluded
AND
Diagnosed after 4th year of life (although symptoms may have begun earlier)
AND
No evidence of a profound T cell deficiency(2 or more of):
CD4 numbers/microliter: 2-6y <300, 6-12y <250, >12y <200
% naive of CD4: 2-6y <25%, 6- 16y <20%, >16y <10%
T cell proliferation absent

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What is SpAD and how is it treated?

A

It is possible to have normal total antibody levels, but fail to produce antibodies to certain types of antigens (particularly polysaccharide)
This can be clinically significant, resulting in recurrent bacterial infections and risk of bronchiectasis

By definition IgG, IgA and IgM levels are normal
Specific bacterial antibodies, particularly to Strep pneumoniae (Pneumococcus) and Tetanus should be checked.
If low, this does not necessarily mean a problem (may not have been vaccinated or significantly exposed
Test vaccination given (e.g. PPV23), and levels repeated at 4-6 weeks
Failure to adequately respond suggests SpAD
Diagnostic criteria also required no evidence of T cell defect (combined immunodeficiency)

Treatment

Prophylactic antibiotics in first instance
Immunoglobulin replacement if ongoing recurrent infection

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

How does selective IgA present?

A

Selective IgA deficiency (absent IgA, IgG and IgM normal) is common (approx. 1/800), usually incidental finding (Coeliac screening) and mostly not clinically relevant

In absence of recurrent infection no further investigation needed

Rarely it can be associated with other antibody deficiencies (e.g. specific antibody deficiency) so if recurrent infections warrants investigation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

What are the Pathogens seen in combined T and B cell deficiency?

A
bacterial
intracellular (mycobacteria)
Salmonella spp
 fungal
Candida spp
Aspergillus spp
Cryptococcus neoformans
 protozoal
Pneumocystis carinii
Toxoplasma gondii
Cryptosporidia
Viral
Respiratory: RSV, Parainfluenzae
GI: rotavirus (vaccine strain), norovirus
Other: CMV, adenovirus
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

What can cause SCID?

A

Severe combined immunodeficiency(SCID,Glanzmann–Rinikersyndrome,alymphocytosis)

Definition: A rare genetic condition caused bynumerous genetic mutations that result in the defective development of functionalB cellsandT cells.

Etiology:various mutations, the most common of which are:

X-linked recessive: mutations in thegeneencoding the commongamma chain →defectiveIL-2Rgamma chain receptor linked to JAK3 (mostcommonSCIDmutation)

Autosomal recessive

Adenosine deaminase(ADA)deficiency→accumulation of toxic metabolites(deoxyadenosine anddATP) and disruptedpurinemetabolism →accumulation ofdATPinhibits the function of ribonucleotidereductase →impaired generation of deoxynucleotides

Janus-associatedkinase3 (JAK3) deficiency

RAGmutation results in faultyVDJ recombination(see “Immunoglobulinproperties”).

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

How does SCID present?and how is it diagnosed and managed?

A

Clinical features

Normal atbirth

Severe,recurrent infections: bacterialdiarrhea, chronic candidiasis(thrush), viral andprotozoalinfections

Failure to thrive

Chronic diarrhea

Lymph nodesandtonsilsmay be absent

Diagnosis

QuantitativePCR:↓T-cellreceptor excision circles (TRECs)

Flow cytometry:absentT cells

CXR: absentthymic shadow

Lymph nodebiopsy: absentgerminal centers

Treatment

IVimmunoglobulins0

PCP prophylaxis

Bone marrow transplantorstem cell transplantation

Avoidance oflive vaccines

Prognosis: often fatal in the first year of life if left untreated[ref]

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

What is Wiskott Aldrich syndrome and how does it present?

A

Definition:genetic condition characterized byimpaired function ofT cellsandthrombocytopenia

Epidemiology: occursprimarily in males

Etiology:mutatedWASp gene(X-linked recessiveinheritance) →impaired signaling toactincytoskeletonreorganization →defectiveantigenpresentation

Clinical features

Onset of symptoms: frombirth

Classic triad

Purpura(bleeding diathesis)

Eczema(high risk ofatopicdisorders)

Recurrentopportunisticinfectionswith encapsulated organismsin the first years of life(e.g.,otitis media)

Increased risk of autoimmune diseases and hematological malignancies(e.g.,lymphoma,leukemia)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

How can wiskott Aldrich syndrome be diagnosed and managed?

A

Diagnosis

Normal or↓IgGandIgM

↑IgEandIgA

Thrombocytopeniawithsmallplatelets

Genetic analysis (confirmatory test): mutatedWASpgene

Treatment

IV immunoglobulintherapy

Prophylacticantibiotics

Platelet transfusions

Stem cell transplantationmay be curative.

Prognosis:shortened life expectancy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

What is Omenn’s Syndrome?

A

Omenn syndrome is an autosomal recessive form of severe combined immunodeficiency (SCID) characterized by erythroderma (skin redness), desquamation (peeling skin), alopecia (hair loss), chronic diarrhea, failure to thrive, lymphadenopathy (enlarged lymph nodes), eosinophilia, hepatosplenomegaly, and elevated serum IgE levels.[1][2][3] Patients are highly susceptible to infection and develop fungal, bacterial, and viral infections typical of SCID. In this syndrome, the SCID is associated with low IgG, IgA, and IgM and the virtual absence of B cells. There is an elevated number of T cells, but their function is impaired.[1] Omenn syndrome has been found to be caused by mutations in the RAG1 or RAG2 genes.[1][3] Additional causative genes have been identified.[1] Early recognition of this condition is important for genetic counseling and early treatment. If left untreated, Omenn syndrome is fatal. The prognosis may be improved with early diagnosis and treatment with compatible bone marrow or cord blood stem cell transplantation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

What are the deficiencies of the innate immunity?

A

Phagocyte disorders
Reduced numbers
Reduced function

NK cell defects

Cytokine deficiencies

Toll-like receptor defects

Complement deficiency

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

What are the common phagocyte deficiency?

A

Neutrophils are the chief phagocyte
Function to isolate, engulf and kill pathogens
Express adhesion receptors and complement receptors to facilitate uptake of opsonised dangerous elements.
Defects in neutrophils (function or number)
Account for nearly 20% PIDs

Include chronic granulomatous disease, Chediak-Higashi syndrome, Griscelli syndrome, leukocyte adhesion deficiency, neutrophil granule deficiency, myeloperoxidase deficiency, cyclic neutropenia, severe congenital neutropenia (Kostmann syndrome) & x-linked neutropenia.
Can be secondary too

Myeloperoxidase deficiency

G6PD deficiency

Both present with similar presentations to CGD but milder forms.
Diagnosis by measuring enzyme levels

Leukocyte adhesion deficiency
Rare
Inability of leukocytes to localise to sites of inflammation due to defective adherence mechanisms.
3 types
Clinical manifestations vary but all have defect in CD18 present on surface of leukocytes
CD18 is the beta chain of 3 integrin receptors – LFA-1, MAC-1 and P15-/95
Complete deficiency of CD18 results in death in early life but those with partial defects benefit from prophylactic and acute antibiotics
BMT may be required

Chediak-Higashi syndrome
Abnormal neutrophil granules and defective killing
Oculocutaneous albinism, neurological symptoms and increased pyogenic infections
Can develop unchecked inflammation
HSCT can cure immunological defects but not neurological symptoms
Griscelli syndrome
Global pigmentary dilution with sivery gray hair
Abnormal management of intracellular granules
Pyogenic infections
HSCT can cure immunologic abnormalities

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

How does Chronic granulomatous disease occur and present?

A

Defect in NADPH oxidase complex resulting in inability to produce respiratory burst.
Several components of NADPH complex encoded by different genes
One of these is on x chromosome so can get x-linked and autosomal recessive forms
Failure to kill micro-organism leads to granuloma formation

Key features
Early presentation – usually
Abscess of skin and deep seated infections of lungs, lymph nodes, liver and bones
Catalase positive bacteria – Staphylococcus, Kebsiella, Serratia & Burkholderia
Fungal infections – Aspergillus (historically leading fatal cause of death)
Inflammatory bowel disease

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

How can Chronic granulomatous disease be diagnosed and managed?

A
Neutrophil assay
Dihydrorhodamine test (DHR): flow cytometry test showing abnormal NADPH oxidase activity (inability to metabolize dihydrorhodamine to fluorescent product, rhodamine → decreased green fluorescence) [21]

Nitroblue tetrazolium dye reduction test: negative, i.e., incubated leukocytes fail to turn blue when exposed to nitroblue tetrazolium
Hypergammaglobulinemia
Anemia
Genotyping is confirmatory

Culture for bacteria and fungi
Evidence of gut inflammation
Evidence of obstruction e.g. urethra secondary to granuloma

Total numbers of neutrophils are normal on FBC

Treatment
Prophylactic antibiotics
Prophylactic anti-fungals
Interferon Gamma
Bone marrow transplantation
? Gene therapy
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
28
Q

What can cause Neutropenia?

A

Severe congenital, cyclic or x-linked
Septicaemia, bacterial respiratory infections, soft tissue infections, gingivstomatitis, periodontitis and oral, vaginal and rectal ulcerations
Severity parallels the deficiency

Diagnosis
Neutrophil count on FBC
Persistent or cyclical drop every 21 days

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
29
Q

What are the causes of Natural killer defects and how does it present?

A
Function to control infection through
Cytotoxicity
Cytokine production
Co-stimulation of other cells
NK cell deficiencies may be found in association with other immunological conditions e.g. XLP (x-linked lymphoproliferative disorder), Wiskott-Aldrich syndrome, and NF-kB essential modulator (NEMO deficiency)
Can be secondary
Meds, malignancy or infection

Primary causes
Reduced numbers / absent
GATA2 ( a haematopoietic transcription factor) deficiency
Reduced function / normal number
Can again be secondary (meds, malignancy, infection)

Key features
Herpes virus infection – VZV, CMV, EBV and HSV
Unusual features of HPV – excess malignancy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
30
Q

What are cytokines defects?

A

Autosomal recessive
Increased susceptibility to mycobacterial disease
Patient with IL-12 deficiency also develop susceptibility to salmonellosis
Diagnosis
Measurement of cytokine levels (specialist tests)
IFN- gamma levels low in IL-12 deficiency
Raised in IFN-gamma receptor deficiency
Treatment
antimycobacterial regimens, prophylaxis, IFN-gamma, HSCT

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
31
Q

What are Toll like receptor function defects?

A

TLRs
= pattern recognition receptors for lots of molecules (self and non-self) that contain danger signals.
Key initiators of innate immune response
Some defects affect a number of TLRs by impairing signalling pathways downstream of the TLR
E.g. IRAK-4 and MyD88 – patients susceptible to pyogenic organisms
Investigations (specialised)
Measure production of cytokines after exposure of PBMC (peripheral blood mononuclear cells) to TLR ligands

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
32
Q

What are complement deficiency?

A

Increased susceptibility to infection

Increased susceptibility to autoimmunity

Hereditary angioedema

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
33
Q

What is Secondary Immunodeficiency?

A

Immune system is compromised due to an extrinsic factor

Rather than an intrinsic genetic defect as seen with primary immunodeficiency (PID)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
34
Q

What is Secondary Immunodeficiency and what’s important to ask in the history?

A
Increased susceptibility to infections 
Unexpected severity 
Unusual infections 
Main difference from Primary Immunodeficiency  (PID) 
Age of onset 
External cause 
More common than PID 
Ask 
Type of infections 
Duration of symptoms 
Severity of symptoms and 
Medication Use 
Other medical conditions 
Identify any organisms cultured
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
35
Q

What are 10 warning signs of immunodeficiency(both primary and secondary

A

Four or more infections requiring antibiotics within one year (eg, sinusitis, bronchitis, pneumonia, otitis media, especially with perforation).
Two or more serious sinus infections within 1 year
Two or more months on antibiotics with little effect
Two or more pneumonias within one year
Failure of an infant to gain weight or grow normally
Recurrent, deep skin or organ abscesses
Persistent thrush in mouth or fungal infection on skin
Need for intravenous antibiotics to clear infections
Two or more deep seated infections including septicemia
A family history of primary immunodeficiency.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
36
Q
  • How do biological therapies cause immunodeficiency?
A

Likelihood of clinically significant infection depends
action of drug
treatment duration
Underlying disease process
Patient co morbidity
Concomitant use of other immunosuppresive medications.

Monoclonal Antibodies to B cells 
Monoclonal Antibodies to T cells 
Anti Cytokine therapy 
Agents disrupting T cell Costimulation 
Agents inhibiting leucocyte Movement 
Monoclonal Antibodies to Complement Proteins
Small Molecule Kinase Inhibitors 
Checkpoint Inhibitors
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
37
Q

What are the common causes of secondary immunodeficiency

A
Severe Malnutrition 
Affects 50% of population is some countries 
Age extremes (young and old) 
Infections 
HIV 
Drugs –most common
Immunosuppressives medication 
Prednisolone 
Monoclonal Antibodies 
Anti convulsants  
Anatomic Abnormality 
Diseases causing protein loss 
Nephrotic syndrome 
Protein losing enteropathy 
Haematological Malignancies 
Surgery and trauma 
Burns 
Disruption of epithelial barriers 
Splenectomy  
Metabolic Disorders
Diabetes
Uraemia 

Both the underlying disease and the treatment contribute in different ways to SID
CLL
Multiple Myeloma
Non Hodgkins lymphoma

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
38
Q

What Investigations can be done and how can secondary immunodeficiency be diagnosed?

A
FBC and film 
Immunoglobulins and Electrophoresis 
Serum Free Light Chains
Specific Antibodies 
Pneumococcal and Tetanus 
Lymphocyte subsets 
Urine protein/creatinine Ratio

Treatment
Removal of the causative agent
Consider Antibiotic prophylaxis
In some cases consider replacement immunoglobulin therapy

If untreated
Infections and end-organ damage e.g bronchiectasis
Significant morbidity and mortality.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
39
Q

What is flow cytometry?

A

The Flow Cytometry laboratory uses the flow cytometer to detect different populations of blood cells in the patient samples. The laboratory also provides a host of functional immunological testing as well as panels for haematological malignancies. In some hospitals it helps to assess and prepare samples for bone marrow transplants. A few common tests are mentioned below. If you are interested, we would encourage a visit to the Flow laboratory to see the full range of testing available.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
40
Q

How are Lymphocytic subsets interpreted?

A

Lymphocyte subsets are a panel of cells counted using a flow cytometer using labelled fluorochromes that emit light at different wavelengths of light.

The cells are first separated by their size and granularity as above, Lymphocytes, seen on the plot above, are then separated based on their attachment to specific fluorochromes labelled antibodies that bind to varies clusters of differentiation belonging to each cell population (e.g. CD3 for T cells). Each population is expressed as a percentage of all cells in the sample. A set number of beads are also added which can be expressed as a % of all cells counted. As the number of beads added is known, this is used to count the actual number of each cell population in the sample.

The basic panel includes:

  • Numbers of total lymphocytes
  • T cells (CD3+)
  • B cells (CD19/20+)
  • NK cells (CD16/56)
  • CD4+ (T helper cells) and
  • CD 8+ (T cytotoxic cells).

Lymphopaenia of different patterns is seen in both primary and secondary immunodeficiency (discussed in other resources). It can also be due to losses from gut, kidneys or thoracic duct drainage. Severe combined immunodeficiency for example is almost always seen with low T cells, with or without the involvement of B cell and NK cell lymphopaenia. CD4+ cells can be low with infection, malignancy or due to drugs. Absent B cells may be seen in immunodeficiency such as secondary agammaglobulinaemia. Lymphocytosis can be seen after viral infections or due to leukaemia and lymphoma. It is important to note that lymphocyte subsets are very tricky to interpret in the middle of an acute infection as any high or low counts could be due to ongoing inflammation, rather than the true baseline for the patient.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
41
Q

What other functional tests can be used?

A

Neutrophil Oxidative Burst:

This is a functional test that looks at the neutrophils ability to phagocytose and kill microbes by testing the activity of NADPH oxidase. Defective neutrophil function should be investigated in patients suspected of having Chronic Granulomatous Disease. CGD is characterised by repeated and life-threatening infections caused by bacterial and fungal organisms. It may mimic inflammatory bowel disease and lead to malabsorption and obstruction of the bowel. Abscesses involving the liver, lungs or lymph nodes are often found.

The cells are stimulated to activation and then a dye is used to see the “oxidative burst”. If this is abnormal, further tests are then considered to look for the specific cause of the defect.

T cell proliferation Assays

Upon interaction with microbes, T cells rapidly proliferate to propagate the adaptive immune response. Defects in these pathways can cause immunodeficiency. These assays look for defects in T cell proliferation by subjecting cells to various stimuli, mimicking different parts of the activation pathways and then incubating them for 72 hours. The cells are then counted and compared with a normal control to ascertain where in the pathway a defect might be. This assay is used for diagnosis as well as monitoring of patients post bone marrow transplant.

NK Cell Granule Release Assay

Defects in the cellular toxicity of NK cells and cytotoxic T cells are a feature in Haemophagocytic Lymphohistiocytosis (HLH). HLH is a life threatening immune disorder of severe hyper-inflammation caused by uncontrolled proliferation of activated lymphocytes and histiocytes. This assay is used to analyse resting and activated NK cell degranulation, looking for the products of degranulation after artificially stimulating NK cells.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
42
Q

What are protein assays?

A

The proteins laboratory offers assays to look at immunoglobulin levels, serum electrophoresis and subsequent immunotyping/immunofixation of any paraproteins found. It also assays serum light chain, complement activity (classical and alternative pathway) and other tests for complement components. A few common tests are mentioned below. If you are interested, we would encourage a visit to the Proteins laboratory to see the full range of testing available

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
43
Q

How can Immunoglobulin levels be interpreted?

A

An immunoglobulin panel consists of IgG, IgM and IgA. IgM, produced first, is often the first antibody to be lost in immunodeficiency. Isolated low IgM can be seen in lymphoproliferative diseases. High polyclonal IgM can be seen in liver diseases and other inflammatory conditions. Raised polyclonal IgA can often be seen in the elderly, but can also be raised due to chronic infection and inflammation. Polyclonally raised IgG can be seen in a reactive state as the other two, but very high levels of polyclonal IgG can be seen in Sjogren’s syndrome and HIV.

Immunoglobulin levels cannot reveal if the rise is due to monoclonal or polyclonal increase. Therefore it is always advised to interpret these with serum electrophoresis (+/- serum free light chains), which can detect the presence of a paraprotein.

In some cases, IgE is also measured. It can be >50,000 (reference range <100) in patients with Hyper IgE syndrome.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
44
Q

What is serum electrophoresis?

A

An immunoglobulin panel consists of IgG, IgM and IgA. IgM, produced first, is often the first antibody to be lost in immunodeficiency. Isolated low IgM can be seen in lymphoproliferative diseases. High polyclonal IgM can be seen in liver diseases and other inflammatory conditions. Raised polyclonal IgA can often be seen in the elderly, but can also be raised due to chronic infection and inflammation. Polyclonally raised IgG can be seen in a reactive state as the other two, but very high levels of polyclonal IgG can be seen in Sjogren’s syndrome and HIV.

Immunoglobulin levels cannot reveal if the rise is due to monoclonal or polyclonal increase. Therefore it is always advised to interpret these with serum electrophoresis (+/- serum free light chains), which can detect the presence of a paraprotein.

In some cases, IgE is also measured. It can be >50,000 (reference range <100) in patients with Hyper IgE syndrome.

Serum electrophoresis is useful to investigate if there is a paraprotein present ( a marker of plasma cell disorders such as multiple myeloma).**A paraprotein is the immunoglobulin product of a single cell clone. It will have only one heavy chain type (e.g. IgG, IgM, IgA or IgD) and/or one light chain type (kappa or lambda). On serum electrophoresis it has the same size and charge and so migrates as a “band” that can be quantified.

Check table in notion.

Immunofixation

Immunofixation is a process where multiple samples of the patient sample are run on gel electrophoresis, which each sample stained for a particular heavy or light chain. This is useful in typing the paraprotein when found, and also to find small paraproteins that may be hidden under the beta and gamma curves. In the examples below we see some paraproteins:

One band in the same location in IgG and lambda regions showing an IgG lambda paraprotein. Serum free light chains if measured in this case may show an increase in lambda chains.

Two bands seen in the same location in the IgG and kappa regions, showing two separate IgG kappa paraproteins. Serum free light chains if measured in this case may show an increase in kappa chains.

In the resources section below you will find The Newcastle upon Tyne Hospitals NHS Foundation Trust guidelines for the interpretation and management of immunoglobulins and paraproteins in adults.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
45
Q

What are complement assays

A

The complement cascade comprises of over 20 proteases that form part of the innate immune system, which helps to fight invading microbes in many ways. One such way is by formation of the membrane attack complex. Deficiency of complement components can lead to immunodeficiency amongst a number of other issues. This cascade is also tightly regulated, failure of which can lead to disorders of overactive complement (such as C3G glomerulonephropathy and atypical haemolytic uraemic syndrome). These first line assays, measure the activity of the classical and alternate pathways by simulating an “invading organism” in the patient’s sample to activate the complement. Any deficiencies will show as decreased activity when measured by analysers, prompting further investigations into the individual components of the pathway.

46
Q

What are the stages of transplant rejection?

A

Hyperacute
Minutes to hours
Pre-existing antibody

Acute
Days to weeks
Cellular (T-cell mediated)
Humoral (antibody production requiring T and B cell function)

Chronic
Months to years
Complex aetiology

47
Q

What happens in hyper acute rejection?

A

Pre-existing anti-donor antibodies in recipient (previous pregnancy, transfusion, transplantation etc.)
Targets are mainly blood group antigens and MHC molecules
Now very rare due to advances in screening and cross-matching

Upon transplantation:
Rapid binding of antibodies to graft antigens
Activation of complement
Cell lysis, increased leucocyte recruitment / inflammation
Endothelial activation, release of pro-thrombotic substances (e.g. Von Willebrand factor)
Platelet aggregation, thrombosis, and occlusion of graft microvasculature

Rapid extensive thrombosis and graft infarction, usually needing graft removal

48
Q

What happen in acute rejection?

A

Key step is recognition of donor antigens by recipient T cells
Donor antigens presented to T cells either on donor antigen presenting cells (APCs) (Direct) or processed and presented by recipient APCs (indirect

If APCs are activated they express co-stimulatory molecule (e.g. B7) that bind receptors on T cells (signal 2)
T cells become activated, proliferate and differentiate into effector cells

CD8 (cytotoxic) T cells infiltrating the graft
Recognise foreign MCH class 1 molecules on donor cells
Kill the graft cells, causing tissue damage

CD4 Th(helper)1 effector cells infiltrating the graft
Recognise donor MHC molecules, release proinflammatory cytokines (IFN-γ, TNF)
Recruitment of inflammatory neutrophils and macrophages
Tissue damage, altered vascular function, ischaemia

CD4 Th2 effector cells help B cells, which proliferate and differentiate into plasma cells
Donor specific plasma cells produce antibodies targeting donor antigens (donor specific antibodies - DSAs)
Circulating DSAs bind to graft endothelial cells, activate complement, endothelial cell damage, microvascular thrombosis in graft

49
Q

How can Acute rejection be diagnosed?

A

Acute rejection presentation:
Acute deterioration in graft function (rise in creatinine and decreased urine output in renal, deranged LFTs in liver, cardiac failure in heart etc.)
Pain in region of graft, and graft oedema

Screening tests for rejection include serial monitoring of graft function (e.g. U&Es, urinalysis in kidney, LFTs in liver, PFTs in lung, echo in heart etc.)
Differential diagnosis includes infection, immunosuppressant toxicity
Diagnosis is with biopsy showing characteristics histological findings
Serological tests also used to identify donor-specific antibodies

50
Q

Why does chronic rejection occur?

A

Occurs over 6 months after transplantation, and is the major cause of long-term graft loss
Main features
Vascular disease within the graft (transplant vasculopathy)
Accelerated arteriosclerosis and luminal narrowing of graft vesseld
Development of fibrosis within the graft tissue

Chronic inflammation targeting the graft vasculature, and non-immune mechanisms are all thought to drive these processes
Both cellular and antibody-mediated mechanisms thought to contribute
Other proposed factors include calcineurin inhibitor toxicity

51
Q

How can rejection be prevented?

A

ABO Blood Group Compatibility
Required for solid organ transplant (preferred but not required for HSCT)

Histocompatibility (HLA Matching)
Matching of HLA alleles, particularly DLA-DR, HLA-A and HLA-B
The matching of DLA-C, HLA-DP and HLA-DQ is preferred but not always required
Requirements vary by organ type

Cross-matching
Physical cross-match: recipient serum mixed with separated donor lymphocytes (B and T cells separately)
Cytotoxic reaction indicates preformed antibodies (donor-specific antibodies – DSA)

Virtual cross-match: looking at whether relevant anti-HLA antibodies have been detected previously in recipient’s serum
Multiplex serological assays looking for anti-HLA antibodies

Induction at time of transplant:

Combination treatment with:
Steroid (IV methylprednisolone)
Calcineurin inhibitor (tacrolimus or ciclosporin)
Blocks T cell activation (calcineurin pathway of TCR signalling)
Antiproliferative agent (e.g. Mycophenolate mofetil – MMF)
Other anti-T cell therapies:
Basilixumab (anti-IL2 mAb, prevents T cell proliferation)
If high risk also T cell depleting induction therapy with ATG (anti-thymocyte globulin) or alemtuzimab (anti-CD52 mAB)

Long-term maintenance immunosuppression is required
Balance between preventing rejection and adverse effects (including infection and malignancy)

52
Q

What is the recommended common triple drug regimen for transplant rejection

A
Commonly a triple drug regimen with
Corticosteroid
Calcineurin inhibitor (tacrolimus or ciclosporin)
Antiproliferative agent
Azathioprine
Mycophenolate mofetil (MMF)
Sirolimus (rapamycin)
53
Q

How can rejection be treatment?

A

Cellular Rejection (T-cell mediated rejection)

Treated with increased immunosuppression

High dose puled IV methylprednisolone
Methylprednisolone 500mg IV daily for 3 doses

With or without T cell depleting therapy, depending on severity
Anti-thymocyte globulin (ATG)

Usually responds well to treatment

Acute Antibody-Mediated Rejection
Potent immunosuppression and treatment to remove or suppress production of donor specific antibodies (DSAs)

Example regimen (adapted from http://edren.org/ren/handbook/transplant-handbook)
Methylprednisolone IV 500 mg daily for 3 days
Plasma exchange (plasmapheresis) - to directly remove DSAs
High dose (immunomodulatory dose) IV immunoglobulin
Anti-B cell agents
Bortezomib (proteasome inhibitor – depletes plasma cells), or
Rituximab (anti-CD20, B cell-depleting agent)
Other immunosuppression continues as standard
Infection prophylaxis including co-trimoxazole and valganciclovir

Responds less well than cellular rejection

Chronic Rejection
Difficult, no specific treatment

Management of complications as appropriate, e.g.
Treatment for heart failure in heart transplant
Dialysis in renal failure
Other organ specific treatments as indicated

End-stage chronic rejection may be an indication for re-transplantation if feasible

54
Q

What is GvHD?

A

Similar but opposite to graft rejection (despite the paradox)
Graft contains donor T cells, to which the recipient is foreign
The graft mounts an immune response against the host (to be expected

Associated primarily with allogeneic haematopoietic stem cell transplantation (HSCT)
Can also occur in:
Solid organ transplantation (e.g. liver, small bowel)
Transfusion on non-irradiated blood products (rare severe complication, primarily in immunocompromised individuals)

3 stages
Activation of host APCs
Damage to host tissue by underlying disease and conditioning treatments causes cytokine release and stimulation of APCs
Donor T cell activation
Donor T cells recognize alloantigen on both donor and recipient APCs in lymph nodes, become activated, proliferate and differentiate into effector cells
Cellular and Inflammatory Effector Stage
Activated donor CD8 (cytotoxic) T cells migrate from lymph nodes to affected organs and kill host cells causing tissue damage
Release of inflammatory cytokines (e.g , influx of inflammatory cells (e.g. neutrophils) mediating further tissue damage

Acute
Onset < 100 days after transplant
Affects 3 sites skin, liver and gut

Chronic
Can affect a wide variety of organ sites
Most cases evolve from acute GvHD
20% occur de novo
10% occur after acute GvHD has resolved
55
Q

How does acute GvHD rejection present?

A
Acute
Skin
Painful or pruritic erythematous macules
Confluent erythema, erythroderma
Subepidermal bullae, vesicles, desquamation
Liver
Deranged LFTs
Jaundice	
Gut
Abdo pain
Diarrhoea
GI bleeding
Ileus
grade
skin stage
liver stage
gut stage
function impaired
0 (none)
0
0
0
0
I (mild)
1-2
0
0
0
II (moderate)
1-3
1
1
\+
III (severe)
2-3
2-3
2-3
\++
IV (life threat)
2-4
2-4
2-4
\+++

Diagnosis
Clinical evidence of dysfunction of affected organ
Symptoms and signs
Deranged LFTs

Biopsy of skin, liver or gut to confirm

56
Q

How does chronic GvHD present?

A
Skin
Same as acute GvHD
Atrophy and erythema of oral mucosa
Sclerodermatous skin changes
Joint contractures

Pulmonary
Obstructive lung disease
Dyspnoea, wheeze, cough
Non-responsive to bronchodilators

Neuromuscular
Weakness
Neuropathic pain
Muscle cramps

Ocular
Sicca syndrome
Haemorrhagic conjunctivitis

Gut
Same as acute GvDH
Also strictures and dysmotility

Liver
Same as acute GvDH
Rarely portal HTN, cirrhosis, liver failure

57
Q

How can GvHD be prevented and managed?

A
Prevention
Donor selection (choose good match)
Depletion of T cells from donor graft
Drugs to suppress donor T cells 
steroids, ciclosporin, MMF

Treatment
Depends on severity
If mild skin may be only topical steroids
Systemic steroids and MMF if more severe
Very severe not responsive to high dose steroids - ATG and other T cell targeted therapies – outlook is poor

In malignant disease treating mild GvHD must be balanced against potential benefit from graft versus tumour effect

58
Q

What is immune tolerance?What are the different types?

A

Must be able to react to harmful foreign antigens (pathogens) and altered self (malignancy), but not self antigens
This lack of reactivity to self is known as immune tolerance

Self-tolerance
fundamental property of the normal immune system
failure results in immune reactions against self antigens e.g. autoimmunity
multiple tolerance mechanisms normally prevent autoimmunity

Lymphocytes that recognise self antigens are killed or inactivated
Self-tolerance may be induced in
immature self-reactive lymphocytes in the generative lymphoid organs (central tolerance)
mature lymphocytes in peripheral sites (peripheral tolerance)

59
Q

How does central tolerance develop?

A

T cells precursors are formed in the bone marrow and migrate to the thymus, where the immature cells are called thymocytes

During T cell development, thymocytes produce their T cell receptor and undergo a 2 step “education” process, ensuring
They are able to interact with self MHC (otherwise would be useless)
Self-reactive cells are deleted, to prevent autoimmunity
Some of the “self-reactive” cells in the CD4+ lineage survive and are directed to become regulatory T cells (Tregs)

Positive selection
choosing T cells that can interact with own MHC
Negative selection
deleting or inactivating T cells that bind strongly to self antigen in association with MHC

Autoimmune regulator (AIRE) gene
allows expression of peripheral tissue antigens in the thymic medullary epithelial cells
used to test the T cells to check if they are self-reactive

B cell similar-check notion

60
Q

How does Peripheral resistance develop?

A

Multiple mechanisms prevent any self-reactive T cells in the periphery from reacting to self antigens

Ignorance - Immune privileged sites: eye/brain/testes
Anergy: TCR engaged without concomitant co-stimulation
Suppression: Regulatory T cells (Treg) can suppress effector functions of other immune cells and enforce tolerance
Deletion: via apoptosis – Activated T cells upregulate death receptors (FAS) making them susceptible to apoptosis

Regulatory T cells can suppress immune responses through multiple mechanisms, including
Compete with other T cells for co-stimulatory ligands on APCs (express CTLA-4, binds B7) and IL-2 (express high affinity IL2 receptor, CD25)
Downregulate APCs (direct cell-cell interaction and cytokines)
Release anti-inflammatory cytokines (IL10, TGF-β)

Down-regulating Immune response

Appropriate immune regulation requires appropriate downregulation of immune responses, as well as control of initiation
Apoptosis (programmed cell death) of immune cells, especially lymphocytes, is essential for this
One mechanism of this is through cell surface ”death” receptors (e.g. FAS, expressed on activated T and B cells)
FAS on cell surface interacts with FAS-L (expressed on CD8 T cells, NK cells, and a variety of others) triggering activation of caspases, ultimately leading to apoptosis of FAS expressing lymphocyte (Activation-induced cell death, AICD)
FASL is also expressed in immune-privileged sites (e.g. cornea, testes), and on some cancer cells, preventing immune responses from T cells

61
Q

What genetic defects can lead to autoimmunity?

A

AIRE deficiency

Autoimmune polyendocrinopathy, candidiasis and ecto-dermal dysplasia
A rare but good example of when central T cell tolerance is impaired
Monogenetic, autosomal recessive
AIRE (autoimmunity regulator) is involved in expression on non-thymic genes within thymus for antigen presentation to thymocytes
Without this, central T cell tolerance is impaired and autoimmunity develops
Endocrine: Hypothyroidism, Addison’s, IDDM etc.
Candidiasis: Develop anti-IL17 antibodies, which impairs IL17-mediated fungal immunity

FOXP3 deficiency(IPEX syndrome)

FOXP3 is essential transcription factor for development of T-reg cells
Deficiency leads to lack of T-reg cells
Severe, complex immune dysregulatory condition
Immunodysregulation, Polyendocrinopathy, Enteropathy, X-Linked
Presents in early childhood with:
Severe eczema
Enteropathy / inflammatory bowel disease
Type 1 diabetes and other endocrine manifestations (e.g. thyroid)
Severe multiple food allergies
Other autoimmune conditions inc. cytopenias, autoimmune hepatitis etc.

ALPS-Defect in FAS/FASL

Autoimmune Lymphoproliferative Syndrome
Monogenetic immune dysregulatory disorder, due to deficiency of FAS or FASL.
Usually autosomal dominant, can be recessive
Presents usually in childhood with:
Lymphoproliferation
Lymph nodes, splenomegaly
Autoimmune disease
Autoimmune cytopenias (haemolytic anaemia, thrombocytopenia etc.)
Autoimmune hepatitis, glomerulonephritis, optic neuritis, vasculitis etc.
Increased risk of lymphoma

62
Q

What can cause autoimmunity and how does it present?

A

Failure of T and B cell tolerance results in
activated T & B cells
antibodies directed against self-antigens
tissue damage & altered physiological function
release of more self antigen
Autoantigens are almost impossible to clear
once initiated, tends to remain active for a very long time
Specific causes of most autoimmune diseases are unknown
Some genetic risk factors have been identified
e.g. certain MHC class I or II molecules, other genes including immune genes e.g. cytokines, immune receptors, complement components
but many predisposed individuals will remain healthy

Epidemiological studies of genetically identical individuals  strong role of environmental factors in the initiation of autoimmunity
Toxins, drugs, viral & bacterial infections
Diet (Western diet)
Stress
Smoking

Rheumatoid arthritis
Systemic lupus erythematosis (SLE)
Granulomatosis with polyangiitis (GPA), and other vasculitides
Psoriasis / Psoriatic arthritis
Graves’ disease
Goodpasture’s
Myasthenia gravis
Type 1 diabetes
Scleroderma
Sjogren’s syndrome
Pemphigus/pemphigoid
Antiphospholipid syndrome
Autoimmune haemolytic anaemia, thrombocytopaenia
63
Q

How can Autoimmune conditions be classified?

A
Difficult
Gell Coombs classification
Organ specific or systemic
 By nature of immune response
B cell: antibody mediated
T cell: cell mediated
Multiple components of the immune system are typically involved, but significance of each varies
Myasthenia gravis (type II)
autoantibodies against Acetylcholine receptor (AChR) play a main role causing in disease symptoms
Type I DM, IBD, psoriasis (type IV)
effector T cells are the main destructive agents (directly cytotoxicity & macrophage activation)
However, as in the response to pathogens, all aspects of the immune system have a role

type II

Antibody mediated hypersensitivity
Mechanism: IgG/IgM antibody-antigen interaction on the surface of target cells
Examples
Goodpasture’s disease (antigen: type IV collagen)
Myasthenia gravis (antigen: AChR)
Graves disease (antigen: TSH receptor)
Note: Antibody formed is a TSH receptor activating antibody

Type III

Immune complex mediated hypersensitivity
Mechanism
immune complex formation
deposition in tissues leading to local or systemic inflammatory reactions
complement activation
recruitment of inflammatory cells, release of mediators and toxic substances (proteases etc.) ➝ tissue damage
Examples
systemic lupus erythematosus (nuclear antigens)
rheumatoid arthritis (antibody antigen)

64
Q

Hows does good pastures occur, present and how is diagnosed?

A

Pathogenesis
Anti-GBM disease
Antibodies formed against the alpha-3 subunit of type IV collagen
Affects alveoli and glomerular basement membrane
Clinical features
generalised: malaise, fatigue, fever, joint aches and pains
lung: haemoptysis, chest pain, cough, shortness of breath
kidney: haematuria, proteinuria, peripheral oedema, uraemia, hypertension

Diagnosis
Anti-GBM antibodies in the serum
Kidney biopsy demonstrating
Crescentic glomerulonephritis
Positive immunofluorescence staining (linear deposition of IgG and complement C3)
Disease can be life threatening
Severe disease may require:
Plasmapheresis
Corticosteroids
Cyclophosphamide
Rituximab (anti-CD20)
Renal replacement therapy (dialysis)
65
Q

What are the genes involved in SLE?

A

Complex multigenic disease
Most disease causing alleles are present in healthy individuals
Usually multiple alleles required, plus environmental trigger for disease

Genes associated with antigen presentation
HLA-DR2 and –DR3: 2-3 fold increase in SLE risk

Genes associated with clearance of apoptotic debris / immune complexes
Increased SLE risk with severe deficiencies in C2 (10%), C4 (75%) and C1q (90%). Also increased in some polymorphisms in MBL and CRP
Genes associated with lymphocyte activation, proliferation and function
BLK, LYN, BANK1 (genes involved in B cell signalling), CTLA-4 (negative co-stimulatory receptor on T cells)
Others include genes encoding cytokines and chemokines, and genes regulating apoptosis

66
Q

What are auto inflammatory syndromes?

A

A distinct set of rare conditions that are caused by a dysregulated innate immune response with resultant activation of the inflammasome and cytokine excess. Also known as Periodic Fever Syndromes
Typically present with recurrent febrile episodes and systemic inflammation affecting multiple organs
Can only be diagnosed when infective conditions, malignancy, allergic and immunodeficiency conditions have been excluded
Manifestations include periodic fevers, neutrophilic rashes or urticaria, serositis, hepatosplenomegaly, lymph-adenopathy, elevated acute phase reactants, neutrophilia, and a long-term risk of secondary amyloidosis.

The innate immune response acts with immediacy to danger or pathogen signals: pathogen-associated molecule patterns (PAMPs) and endogenous damage-associated molecular patterns (DAMPs)

PAMPs and DAMPs activate intracellular inflammasomes which then produce an cascade of inflammatory cytokines such as IL-1, IL-18, TNF-α, IL-6, IL-17, type 1 interferons (IFN-α and IFN-β)

Autoinflammatory syndromes are the result of a disrupted, dysregulated innate immune system causing a pro-inflammatory state, with the final common pathway being activation of the inflammasome, with resultant unopposed cytokine excess

67
Q

What is the pathogenesis and common features of auto inflammatory syndromes?

A

Approximately 30 classified auto-inflammatory syndromes, though all distinct they do share the same key features
Recurrent episodes of fever
Symptoms of inflammation in systems (abdominal pain, chest pain, arthritis) and raised inflammatory markers during attacks (CRP and raised neutrophils).
May be some evidence of chronic inflammation (raised IgG and/or IgA)
Risk of developing amyloidosis with uncontrolled chronic inflammation
We will cover the 3 most common:
Familial Mediterranean Fever (FMF)
Cryopyrin Associated Periodic Fever Syndrome (CAPS)
TRAPS

Pathogenesis
The NRP3 inflammasome is a complex of proteins that activates caspase-1, leading to cleavage of inactive pro-IL-1β to active IL-1β

The monogenetic auto-inflammatory syndromes Familial Mediterranean Fever (FMF) and Cryopyrin Associated Periodic Fever Syndrome (CAPS) are both caused by dysregulation of the NLRP3 inflammasome

68
Q

How does Familial mediatarrarean fever present?

A

Caused by mutation in the MEFV1 gene affecting the production of the Pyrin protein
Autosomal recessive inheritance. Onset <20 years of age
Main ethnic distribution: Turks, Arabs, Jews and Armenians
Clinical features:
Attack duration: typically 1-3 days
Distinguishing symptoms: Fever, serositis, peritonitis, pleuritic,
monoarthritis and erysipelas like skin lesions
Acute attacks: Raised neutrophil counts
Significant risk of amyloidosis: Up to 75%

69
Q

How does Cryopyrin associated fever present?(CAPS)

A

Caused by a gain of function mutation in the NLRP3/CIAS1 gene
Autosomal dominant inheritance. Onset typically < 1 year of age
Main ethnic distribution: White Europeans
The clinical phenotype is a spectrum:
from least to most severe

Familial Cold Urticaria: non-itchy urticaria, red eyes, fevers and arthralgia within hours of systemic exposure to cold. Symptoms may last days.
Muckle Wells Syndrome: As above, but also symptoms of sterile meningitis, notably sensorineural hearing loss. 1in 4 develop amyloidosis.
Chronic Infantile Neurological, Cutaneous and Articular Syndrome (CINCA): Continuous inflammation with no symptom free intervals. Untreated causes very early death

70
Q

How can FMF and CAPS be treated?

A

FMF: Colchicine
Good effect in symptom control
Decreases risk of amyloidosis
Approx. 10% non responders

CAPS: Symptoms all due to uncontrolled IL1b production and therefore can use highly specific and targeted treatments
Anakinra: Human IL1-RA
Canakinumab: Anti-IL1b

71
Q

How TNF receptor associated periodic fevers occur and present?

A

Due to mutation in TNF receptor meaning that it is permanently “switched on”
Current hypotheses:
Reduced shedding of TNF receptor post triggering – pro-inflammatory state by ongoing stimulation of retained cells surface receptor
Misfolded receptors – ligand independent signalling causing cytokine production
Autosomal dominant inheritance
Formerly known as familial Hibernian fever, owing to a higher frequency in Northern Europeans, but seen in many ethnic groups.

The clinical features of TRAPS that distinguish it from other periodic fever syndromes are:
Long durations of attacks: prolonged febrile episodes lasting 3-4 weeks
Severe migratory muscle pain with overlying skin redness
Swelling around the eye (periorbital oedema; often unilateral)
Also have significant abdominal pain (often due to adhesions), chest pain and arthralgia during attacks

During attacks: high markers of inflammation (CRP), high neutrophil count
25% risk of amyloidosis

The clinical features of TRAPS that distinguish it from other periodic fever syndromes are:
Long durations of attacks: prolonged febrile episodes lasting 3-4 weeks
Severe migratory muscle pain with overlying skin redness
Swelling around the eye (periorbital oedema; often unilateral)
Also have significant abdominal pain (often due to adhesions), chest pain and arthralgia during attacks

During attacks: high markers of inflammation (CRP), high neutrophil count
25% risk of amyloidosis

treatment
Mild symptoms: NSAIDs

Etanercept – decoy soluble TNFa receptor that binds TNFa, therefore reducing the binding of TNF to actual receptors. Reduces the frequency and severity of flares

72
Q

How does complement pathway function?

A

Complement is part of the innate immune system

Is a group of plasma proteins important in the destruction of microorganisms

Complement has 3 major effector functions in host defence:
The ability to lyse cells
The ability to opsonize particles (making them easier for phagocytes to engulf)
The ability of the proteins on activation to generate fragments that have potent inflammatory activity

3 main pathways of complement activation:
Classical pathway: Triggered by antibodies that are bound to their antigens
Alternate pathway: Activated by the presence of pathogen (antibody independent)
Lectin pathway: Activated by lectin-type proteins that have already bound to the carbohydrate on pathogens
All pathways ultimately lead to the activation and binding of C3. The pathways then proceed together (terminal pathway) producing a membrane attack complex that forms a transmembrane pore in the pathogen causing cell lysis

C4b,C3b-Opsonization
C3a,c5a-Inflammation
C5,C6,C7,C8-MAC

73
Q

What are the causes of acquired Complement deficiencies?

A

Deficiencies of complement can be inherited or acquired
Acquired complement deficiencies are relatively common and may occur as a result of:
decreased synthesis - the liver is the most important organ for the synthesis of several complement proteins, and therefore, low complement levels are often seen in persons with advanced liver disease
increased protein loss - nephritic syndrome or protein-losing enteropathies
increased consumption - often accompanies immune complex disease, vasculitis, or development of autoantibodies against complement proteins
The association of acquired complement deficiency and increased risk of associated infection is as discussed for inherited versions

74
Q

What are common complement deficiency affecting the classical, alternative and Lectin pathways?

A

Classical
Deficiency of each of the early proteins (C1, C2, C4) of the classical pathway is very strongly associated with the development of systemic autoimmune diseases, notably SLE
Deficiencies also associated with an increase risk of infection with encapsulated bacteria - S. pneumoniae, Haemophilus influenzae, and Neisseria meningitidis

Alternative

Alternative pathway
Properdin deficiency
Properdin is a regulatory protein of the alternative pathway that stabilizes C3 and C5 convertases causing increasing activity and deficiency leads to rapid decay of the convertases and therefore less efficacy
Is inherited in an X-linked fashion
Presents as recurrent severe bacterial infections in childhood. Meningitis due to Neisseria meningitides should raise suspicion of properdin deficiency.

Lectin
Mannan binding lectin (MBL)
is the first protein in the lectin pathway
Gene is highly polymorphic and many mutations cause decreased expression of the MBL protein
Some suggestion of an increased risk of encapsulated bacterial infection in young children (<2 years of age)
Very low MBL levels identified in large numbers of entirely asymptomatic individuals – therefore MBL deficiency is insufficient to cause disease in the absence of other host-defence problems

75
Q

What deficiencies can affect the common pathway?

A

C3 deficiency
Typical presentation:
Life-threatening recurrent infections staring in early childhood
Particularly susceptible to encapsulated organisms (Commonly Strep. Pneumoniae and N. Meningitides)
Associated with immune complex diseases
Approx. 25% develop renal disease
Approx. 25% develop autoimmune disease (most commonly SLE)

C3 Regulatory Proteins: Factor H and Factor I
Both work together as regulators of C3b in plasma, leading to its inactivation and therefore controlling the complement cascade
Mutations in both Factor H or Factor I can lead to development of atypical haemolytic uraemic syndrome which is characterised by haemolytic anaemia, thrombocytopaenia and acute renal failure.

Common Pathways
Membrane Attack Complex
Deficiency of any of the terminal components of the complement cascade results in susceptibility to gram negative bacteria (particularly Neisseria species)
CD59 (MAC-inhibitory protein) is present on cell membranes and is critical for neutralising membrane attack proteins when they bind to our own cells
Patients with paroxsysmal nocturnal haematuria (PNH) have an acquired mutation in the PIGA gene which prevents CD59 being expressed on cell surfaces, and the affected cells are then easily (and abnormally) lysed by complement
PNH is a rare and life threatening condition.
PNH typically presents with red discolouration of urine due to haemoglobin and haemosderin from haemolysis, most commonly first thing in morning. Also notable symptoms of anaemia – tiredness, breathlessness – and increased incidence of thrombosis

76
Q

What Investigations are done for complement deficiencies?

A

In patients with a history of recurrent infection with encapsulated bacteria* from a young age – particularly meningitis – need to exclude complement deficiency

  • S. pneumoniae, Haemophilus influenzae, and Neisseria meningitidis

First line investigation is a CH100 and AP100

Radial immunodiffusion assays
CH100 shows classical pathway
AP100 shows alternative pathway
Solid media has animal red blood cells embedded in it
Patients serum added
Plate incubated at 37oC
If normal complement pathway a “clear zone” forms around the well where the patient serum has lysed the foreign red blood cells

Lysis in the CH100 assay with no lysis in the AP100 assay indicates a deficiency in the alternate pathway (such as Properdin)

Absence of lysis in the CH100 assay with normal lysis in the AP100 indicates a deficiency in the classical pathway (C1, C4, C2).

Absence of lysis in both assays indicates deficiency of a terminal component (C3, C5-C9).

77
Q

How are complement deficiencies managed?

A

For complement deficiencies causing susceptibility to encapsulated bacterial infections prophylactic antibiotics should be given lifelong

For conditions causing inappropriate activation of the complement cascades (aHUS, PNH) then Eculizumab is used
Eculizumab
recombinant humanized monoclonal antibody against the complement protein C5
inhibits terminal complement activation
Be aware of the increased susceptibility of meningococcal infection!!

78
Q

What the different types of autoantibody test?

A

Many autoimmune diseases are known to be associated with presence of detectable autoantibodies
These can be detected in patients’ serum
There are two main types of autoantibody tests, with many variations of each method
Indirect immunofluorescence assays – looking for antibodies in serum binding to tissue fixed on a slide
Immunoassays (e.g. ELISA) – looking for antibodies in serum binging to a purified known antigen fixed on a surface

79
Q

How does Indirect Immunofluorescence work?

A

This method uses slides with tissue fixed on them. These are mostly commercially produced and purchased by the lab
Different tissue is used for different assays, depending on what autoantibodies are being looked for, e.g.
ANA (anti-nuclear antibodies): Hep 2 cells (a human cell line derived from a patient with cervical cancer in 1950s), have a large nucleus allowing easy visualisation of nuclear autoantibodies
Anti-endomyseal antibodies (seen in Coeliac disease): Monkey oesophagus
Patient serum is incubated on the slide, allowing any antibodies specific for antigens in the tissue to bind to it

After incubation, the slide is washed to remove serum and any antibodies not bound to tissue antigens
The slide is then incubated with a secondary antibody specific for human antibodies (usually IgG) labelled with fluorescein (FITC)
The slide is then washed again, to remove any unbound fluorescein labelled antibody
Then viewed under a fluorescence microscope, and fluorescence seen if autoantibody was present in the serum
Fluorescence pattern varies depending on the antigen

Examples
ANCAs
ANCAs are anti-neutrophil cytoplasmic antibodies
Found mostly in vasculitis (e.g. GPA)
Tissue used on slide are fixed human neutrophils
Two main patterns c (cytoplasmic) and p (perinuclear) ANCAs
The main cANCA antigen is PR3 (proteinase 3)

ANA (Anti-nuclear antibodies)
Tissues used include Hep2 cells
Many different ANA target antigens, associated with different diseases
These result in many different patterns
Example shown is homogenous ANA
Homogenous ANA antigens include dsDNA and histones
Disease associations include SLE, juvenile idiopathic arthritis, rarely other connective tissue diseases

Revise the pattern

80
Q

How to perform Immunoassays for antibodies?

A

ANA (Anti-nuclear antibodies)
Tissues used include Hep2 cells
Many different ANA target antigens, associated with different diseases
These result in many different patterns
Example shown is homogenous ANA
Homogenous ANA antigens include dsDNA and histones
Disease associations include SLE, juvenile idiopathic arthritis, rarely other connective tissue diseases

Examples-ENAs

Many immunoassays look for the same autoantibodies as immunofluorescence assays, but the specific target antigen is known
Examples include ENAs (extractable nuclear antigens) e.g. Ro (SSA), La (SSB), Sm, RNP, Scl-70, centromere, Jo-1
These are mostly the various individual antigens that collectively can make up ANA
Associated with connective tissue diseases, including SLE, Sjögren’s syndrome, polymyositis / dermatomyositis, systemic sclerosis, mixed connective tissue disease
Rather than an educated guess at the antigen target from an ANA fluorescence pattern, the antigen is known, and disease associations likely are clearer
However, not all ANA antibodies are easily identified with antigen specific methods, so there is still a role for immunofluorescence

ANCAs are anti-neutrophil cytoplasmic antibodies detected by IIF
cANCA (cytoplasmic) pattern
Associations: vasculitis, most strongly with granulomatosis with polyangiitis (GPA), less so with other vasculitides and rarely seen in infection, rheumatoid arthritis
Antigen usually proteinase 3, but can occasionally be others
pANCA (perinuclear) pattern
Associations: Vasculitis, most strongly with microscopic polyangiitis and eosinophilic granulomatosis with polyangiitis (EGPA), less so with CTDs, and inflammatory bowel disease
Antigen is usually myeloperoxidase (MPO)
Increasingly, immunoassays for anti-MPO and PR3 are used instead of IIF
More specific for vasculitides than IIF ANCAs

Automated Multiplex Autoantibody test

Many labs, including RVI, now use automated multiplex tests for autoantibodies
These use different coloured beads each coated with a different antigen
After incubation with serum and labelling with a secondary fluorescent antibody, sample is analysed by lasers, each bead being read for colour (antigen) and fluorescence (amount of autoantibody bound)
Allows testing for many different autoantibodies at the same time (e.g. a screen of ENAs)

81
Q

How to Identify which autoantibody test to order?

A

There is no such thing, so what should you do…?
Ask the person asking you exactly what tests it is they want
If they are asking this, they probably don’t really know what they want
Be wary of blindly requesting tests. What will you do with the answers?
If investigating connective tissue disease or arthritis, you probably want ANA / ENA (including dsDNA), and if considering rheumatoid arthritis also anti-CCP and rheumatoid factor
If investigating deranged LFTs, you probably want anti-smooth muscle (SMA), anti-mitochondrial (AMA), anti-LKM, and IIF ANA (in RVI this is a “liver autoantibodies” panel)
If investigating acute renal failure, haemoptysis, possible vasculitis, you probably want anti-MPO and PR3 (or ANCAs) and anti-GBM
Many other possibilities exist for different clinical situations. If in doubt ask the lab or your friendly immunologist

82
Q

What is the mechanism of allergy and how can they classified?

A

An allergic reaction occurs within minutes of exposure to allergens
Upon first contact, a patient is sensitised and generates IgE antibodies
These antibodies coat mast cells, causing degranulation on subsequent exposure to allergens
The main mediator of an allergic reaction is histamine
Late phase reactions due to induction of eosinophils and basophils can cause further symptoms a few hours after initial exposure.

Gel and Coombs classification

Most allergies*
Some delayed drug reactions due to Type 4 hypersensitivity
Immediate reaction, within minutes usually
Mediated by IgE antibodies released from mast cells and basophils
Three Phases
Sensitization
Immediate phase reaction

Late Phase Reaction
T helper 2 cells, and the newly recruited eosinophils and basophils secrete pro-inflammatory mediators, cytokines and chemokines,leucotrienes in the late phase which can trigger a second reaction.(6 to 12 hours of after initial symptoms)
Repeat exposure can lead to ongoing local inflammation seen in allergic rhinitis and allergic asthma(structural damage

83
Q

What are the triggers for allergy?

A
Foods (commonest in children)
nuts (peanut, tree nut)
fish, shellfish
wheat, soya, sesame, milk
Drugs (commonest in older people)
Penicillin
Cephalosporins
anaesthetic agents
Venom
Wasp
Bee
Others
Latex
Contrast media
Topical products such as hair dye and salicylates
Excipients such as Polyethylene Glycol (PEG)
Idiopathic
84
Q

What is the effect of histamine release?

A
Bronchoconstriction
Mucous secretion
Reduce cardiac contractility
Increased vascular permeability
Vasoconstriction: reduce blood to tissues
Venodilation: reduced blood to heart
85
Q

How can an allergy present?

A
Respiratory
shortness of breath, tachypneoa
wheeze or stridor
chest tightness
respiratory arrest
Cardiovascular
tachycardia/bradycardia, palpitations
hypotension/collapse
cardiac arrest
Gastrointestinal
abdominal pain
nausea and vomiting
Diarrhoea
Central nervous system
‘Feeling of impending doom’
headache
altered mental status
confusion, drowsiness
Skin
urticaria, angioedema

Mild Symptoms
Oral symptoms
Urticaria
Angioedema (including facial angioedema)

Moderate Symptoms
Abdominal pain
Nausea/Vomitting 
Mild wheeze
“Lump” in throat 
Severe Symptoms or Anaphylaxis
Any compromise of airway, breathing or circulation

Mild-Oral histamines

Moderate-oral histamines and oral corticosteriods

Severe-Adrenaline

86
Q

What are the risk factors for anaphylaxis?

A

Rapid Onset
Foods 30mins
Stings 12mins
Iatrogenic 1min

Background history of asthma most important predictor of reaction severity

Risk factors

Study looking at peanut and tree nut anaphylaxis in UK 1992-2004
1094 patients

Risk factors identified included:
Pharyngeal oedema 3.8x more likely if severe rhinitis present
Tree nuts 2.6x more likely to cause severe reactions than peanuts
Life threatening bronchospasm 6.8x more likely if severe asthma present and 2.7x more likely with mild asthma
Altered conscious level 3.1x more likely in patients with severe eczema

87
Q

How can anaphylaxis be recognised and assessed?

A

Highly likely when all 3 criteria are met:

Sudden onset and rapid progression of symptoms
Life-threatening Airway and/or Breathing and/or Circulation problems
Skin and/or mucosal changes (urticaria, angioedema)

Diagnosis is supported by exposure to a known allergen for the patient

What are the signs and symptoms of anaphylaxis?

Anaphylaxis = respiratory compromise or B.P.
Skin or mucosal changes alone are not a sign of an anaphylactic reaction
Skin and mucosal changes can be absent in up to 20% of reactions
Some patients can have only a decrease in blood pressure
Gastrointestinal symptoms not uncommon
vomiting, abdominal pain, incontinence

Airway
Airways swelling – tongue and throat
Difficulty breathing and swallowing
Sensation the throat is ‘closing’
Hoarse voice
Stridor
Breathing
Shortness of breath
Increased respiratory rate
Wheeze
Confusion – may be a sign of hypoxia
Cyanosis (appears blue) – a late sign
Respiratory arrest
Circulation
Signs of shock- pale, clammy
Increased pulse rate(tachycardia)
Low blood pressure (hypotension)
Decreased conscious level
Myocardial ischaemia / angina
Cardiac arrest
DO NOT STAND PATIENT UP

Disability
Sense of impending doom
Anxiety, panic
Decreased conscious level caused by airway, breathing or circulation problem

Exposure
Look for skin changes
Can be first feature
Present in >80% of anaphylactic reactions
Skin, mucosal or changes of both
Triptase
Released from activated mast cells
Levels stable once collected
Levels peak in 1-2hrs and normalizes within 12-14 hrs
1x gold topped (clotted / serum) tube
Record time taken on sample & in notes
Timing
1-2hrs after start of symptoms (no later than 4 hrs) 
At > 24hrs (or in convalesence)
88
Q

What are the Guidelines available for anaphylaxis?

A

Resuscitation Council
Emergency treatment of anaphylactic reactions
Jan 2008 – review due 2021

Nice Guidance published Dec 2011(r/v’d 2016)
Anaphylaxis: assessment and referral after emergency treatment

BSACI
Specific guidelines (e.g. GA, Nuts, penicillin, milk, egg)
89
Q

How is anaphylaxis treated and what is the role of adrenaline

A

ABCDE
Airway support and oxygenation
lay the patient flat with legs up

Most important drug in treatment of anaphylaxis
Must be given to all patients with life threatening features
Hypotension
Difficulty breathing / swallowing (airway involvement)

Must be given IM
May fail to reverse symptoms in patients on beta blockers (may need additional doses)

Adrenaline acts fast, directly on the factors that cause the life-threatening symptoms of anaphylaxis1

Timely IM injection of adrenaline is critical to receiving physiological benefits2,3

Role of adrenaline-Acts on alpha and beta adrenal receptors

Alpha-Vasoconstriction
peripheral resistance
low mucosal edema

beta-bronchodilation
reduce inflammation
increase cardiac output

Establish airway
High flow oxygen
Iv fluid challenge

Then consider iv chlorphenamine & hydrocortisone – do not delay adrenaline administration to given these.

90
Q

What are advice would you give a patient for follow up and discharge following anaphylaxis?

A

Risk of recurrence of symptoms
Caution in asthmatics
Those with continuing absorption of allergen
Prior history of biphasic reactions (1-20%)
NICE guidelines recommend 6-12 hours from onset of symptoms depending on response to emergency treatment
Consider 3 day course antihistamine (cetirizine)
If known allergy patient and adrenaline autoinjector has been used, it should be replaced prior to leaving
Consider prescribing adrenaline autoinjector if triggers unknown / difficult to avoid
If new patient or if update on diagnosis / self management plan - Refer to allergy clinic

Adrenaline auto injectors

Indicated for anaphylactic reactions to an unavoidable substance

Caution in patients with cardiovascular disease
Beta Blockers

Patients need to carry 2 pens

Training required
Indications for use
Practical aspects of administration

91
Q

What are the different types of allergy?How can they be differentiated

A
Types of Allergy
IgE mediated allergy
Acute onset, Immediate
Release of histamine via IgE mechanisms
Urticaria, angioedema
Non IgE mediated allergy
Delayed onset, T cell mediated 
Release of histamine via non IgE mechanism
Dysmotility, Eosinophilic Oesophagitis, FPIES
Systemic allergy
Immediate - Anaphylaxis
Delayed - Food protein Induced Enterocolitis (FPIES)

Clincal features

Skin
IgE mediated-
Angioedema of the lips, tongue and palate

non IgE mediated-Atopic suppurative eczema

GI
IgE mediated-Faltering growth, oral puritius,abdo pain, vomiting diarrhoea
non IgE mediated-Faltering growth,GORD,perianal disease,constipation

Respiratory
IgE mediated-URTI,nasal itching, sneezing,rhinorrhea
non IgE mediated- persistent wheeze

Diagnostic tests

IgE mediated disease - Helpful
Skin prick tests
Specific IgE blood test (Immunocap)
Component resolved diagnostics	
Non IgE disease  -  Unhelpful
Eosinophils / basophils /mast cells
Biopsies of the gut
Nutrition growth centiles
malnutrition
92
Q

What does atopy mean?

A
An exaggerated propensity in genetically predisposed individuals to produce IgE and Non IgE  responses to common environmental triggers.
The IgE mediated Allergic March
Types of allergic co-morbidities  
Atopic Dermatitis (Eczema)
Food allergy
Allergic Rhinitis
Atopic Asthma
Drug Allergy
93
Q

What is an allergy management plan?

A
Food Allergy Management plan
State the culprit trigger
Name, address, telephone numbers
Outline how to treat mild, moderate and severe symptoms	
Prescribe a ‘Rescue Medication Pack’
Antihistamine (eg cetirizine)
Bronchodilator (eg Salbutamol)
Adrenaline Auto-injector - Risks
94
Q

How does allergy present?

A

Presentations in different circumstances or ethnic groups
Atopic dermatitis
Genetic predisposition – filaggrin mutation
Increased sensitisation across leaky skin
High risk for food allergy
Discoid eczema
Discoid
Not related to food allergy
Eczema and infection
Eczema Herpeticum
Staph Aureus / streptococcus I

Faltering growth -  refer to dietitian
Faltering growth
Symmetrical
IgE and Non IgE food allergy 
Eczema- high risk
Vitamin D Deficiency
Northern counties 
Eczema – barrier treatments 
Rickets
Non IgE mediated cow’s milk allergy
Calcium supplements
95
Q

How can Urticaria and Angioedema be differentiated?

A
urticaria
superficial swelling of the skin (epidermis and mucous membranes) that results in a red, raised, itchy rash
angioedema
a deeper swelling within in the dermis and submucosal or subcutaneous tissues
acute
symptoms < 6 weeks
chronic
symptoms > 6 weeks
on a nearly daily basis

Urticaria
A central swelling of variable size, surrounded by erythema (wheal)
Itchy, burning sensation
Fleeting, usually returning to normal within 30mins – 24 hours
Histamine

Angioedema
Skin coloured swelling of the dermis and deeper subcutaneous tissue
Painful swelling, no itch
Slower resolution compared to wheals, can last up to 72 hours
Bradykinin

96
Q

What are the different types of urticaria and what are the triggers?

A
Chronic spontaneous urticaria (CSU)
 spontaneous appearance of wheals/angioedema or both for > 6 weeks due to unknown causes
 Inducible urticaria
 cold urticaria
 delayed pressure urticaria
 solar urticaria
 vibratory urticaria
 cholinergic urticaria
 contact urticaria
 aquagenic urticaria

Triggers

idiopathic (i.e. CSU)
stress
infection
medications
NSAIDs, opiates
ACEi (angioedema only)
environmental
hot, cold, pressure
minor trauma (dermographism)
exercise
vibration
heat
hot bath, sun
thyroid dysfunction
electrolyte abnormalities
Vit B12, folate, ferritin, VitD
H.pylori infection
urticarial vasculitis
97
Q

What Investigations are done for Urticaria?

A

diagnosis of urticaria is based primarily on the clinical history and appearance of rash
blood tests
FBC, UECs, LFTs, TFTs, Vit B12, Folate, Ferritin, Vit D
C4, C1 inhibitor (for angioedema)
ANA, TPO/TG antibodies (for autoimmunity)
provoking tests
scratch with wooden spatula (dermographism)
ice cube, exercise, pressure, water

Allergy testing
patients often referred to hospital in the belief that CSU is caused by food allergy
expect skin prick testing (SPT)
food is not a cause of CSU, so therefore SPT is rarely indicated
in some patients, the sight of negative SPTs can be reassuring that allergy is not the cause of their symptoms

Prognosis
acute urticaria
excellent
normally self-limiting & short-lived
responds well to standard treatment
chronic urticaria
often relapsing and remitting
spontaneous resolution in 60% of patients within 1 year and 80% of patients by 5 years
20% of patients remain symptomatic 10 years after first presentation
98
Q

How can Urticaria be treated?

A

avoidance strategies
heat, stress, exercise, medications
discontinue ACE inhibitor (causes angioedema only)

2nd generation antihistamines
Cetirizine, Loratadine, Fexofenadine
less sedation than 1st gen (e.g. chlorphenamine)
start with daily dose
titrate to high dose
Cetirizine/Loratadine 20mg bd
Fexofenadine 360mg bd

short course of corticosteroids
if symptoms very severe
e.g. Prednisolone 20mg daily for 3-5 days

leukotriene antagonists

Montelukast 10mg nocte
may be useful if concurrent reactivity to aspirin, NSAIDs, pressure or autoimmune based urticaria

Tranexamic acid
for angioedema only

immunosuppression
Cyclosporine
inhibits mast cell and basophil degranulation
requires monitoring: blood pressure, FBC, UECs, urinalysis
S/E: headache, nausea, tremor, renal impairment
anti-IgE therapy
Omalizumab

99
Q

What is the role of Omalizumab?

A

monoclonal antibody against IgE
used in the treatment of CSU and severe asthma
add‑on therapy for severe CSU in adults and children >12 years if:
evidence of disease severity, e.g. UAS7 score ≥28
failed maximal medical therapy, i.e. antihistamines + leukotriene receptor antagonists
300mg subcutaneous monthly injection
2 x 150mg pre-filled syringes
side effects
injection site reactions
sinusitis, headache, arthralgia, transient worsening of urticaria

NICE recommendations
standard course is 6 months, must be discontinued to assess if there is spontaneous remission
can be restarted if urticaria relapses
if no improvement after the 4th dose, treatment should be reviewed (?needs to be discontinued)
Omalizumab is administered under the supervision of immunology/allergy or dermatology
cost
150mg syringe: £256.15
single dose of 300 mg: £512.30
24‑week course of treatment: £3073.80

Omalizumab home therapy

patients are able to administer their own treatment at home
receive 2-3 training sessions in hospital (follow SOP)
if ok, remainder of injections at home
pros
more convenient/flexible, minimise travel to hospital
cons
requires manual dexterity (or family member/friend), storage of medication, monitoring more difficult, management of side effects

If Omalizumab doesn't work?
?wrong diagnosis
consider other immunosuppressants
cyclosporine
mycophenolate
methotrexate
combination (e.g. Omalizumab + immunosuppressant)
100
Q

What scoring tools can be used to assess severity of Urticaria?

A

validated tool: Urticaria Activity Score(UAS7)
patient records severity of itching and number of wheals daily for 7 days
score <7: good control of disease
score ≥28: severe disease

101
Q

How does Hereditary Angioedema occur and how does it present?

A

Incidence 1:50 000-1:150 000
Autosomal dominant
Defect in SERPING1 gene
No ethnic or sexual predilection

Disorder of C1 inhibitor (C1INH)
Type I (85%)
Low levels of C1INH
Type II (15%)
Normal level but functional defect
Clinical Presentation:
Repeated episodes of oedema:
Face
Extremities 
Genitals 
Intestines
Larynx

Combination and migratory attacks common
Increases over 36 hours
Attack site and severity variable – within same person and family members
No Urticaria

Often a delay in diagnosis > 7 years

Many patients have had emergency abdominal surgery pre-diagnosis

Diagnosis made earlier if family history

Families may accept these attacks as normal for their family

Exacerbated by oestrogens and ACE-inhibitors – must be avoided

102
Q

What are the triggers for Hereditary Angioedema

A

Recognised triggers:
OCP (oestrogen – containing)
Trauma
Infection
Stress
Dental surgery (trigger for laryngeal attack) / medical interventions
Exacerbated by oestrogens and ACE-inhibitors – must be avoided

103
Q

What are the Iab results of Hereditary angioedema

A

Labs:

1) C1INH - low levels, or low function C1 esterase inhibitor
2) Low levels of C4(Also function)

If C4 normal not likely to be due to be HAE

104
Q

What is the management of Hereditary angioedema?

A

Laryngeal oedema:
Prudent use ETT intubation
Monitored setting until resolution of attack
Steroids/antihistamines NOT useful
Nebulised adrenaline / adrenaline may decrease the vascular component of oedema but doesn’t change the underlying process
Specific treatment
C1 inhibitor or Bradykinin inhibitor

Intestinal oedema:
Aggressive replacement fluid losses (vomiting and diarrhoea)
Pain management
Non-sedating anti-emetics
Avoid interventional procedures unless unusual symptoms (hematemesis, PR bleeding)

Established Pharmacologic Treatments:
Prophylaxis:
1) Androgen derivatives
2) Antifibrinolytic agents
3) New therapies

Acute attacks:

1) C1INH concentrate
2) Icatibant

Acute treatment

C1 Inhibitor concentrate - plasma derived
Usually 1000 – 2000 units per intravenous infusion (target 20u/kg)
Safe and effective – no long term side effects reported although is a blood product
Excellent and prompt response in most patients
Some may need second dose
C1 inhibitor concentrate – recombinant
50IU / kg
Made from rabbit milk – caution if rabbit allergy

Bradykinin inhibitors
For acute treatment only
Icatibant 30mg in 3 mls – selective agonist of bradykinin receptors
Slow subcutaneous injection
Frequently self administered

Kallikrein inhibitors
Available in America

Prophylactic therapies

Antifibrolyntics
Danazol (androgenic steroid)
Significant Angioedema at least twice weekly over period of 2 months-C1 inhibitor twice weekly or pre- intervention e.g. dental treatment/ endoscopy
Lanadelumab
Antibody directed at kallikrein 
Subcutaneous injection every 2-4 weeks
87% reduction in attack rate
NICE guidance – must have 2 attacks per week
105
Q

What is Acquired angioedema and how does it present?

A

Acquired deficiency of C1 Esterase
Probably due to production of interfering antibodies
Most commonly B-cell lymphoproliferative disorders (esp. lymphoma) but also in autoimmune disease (e.g. SLE)
More common after 4th decade
Very rare

Clinical presentation:
No family history (distinguish from HAE)
Non-pruritic 
Non-pitting 
Again NOT associated with urticaria
Consider underlying diagnosis
106
Q

How is acquired angioedema investigated and managed?

A

Investigations

Low C1-INH levels
Low C1q levels
Low C4 levels
Low C2 levels
Autoantibodies (look for autoimmune disease)
Immunoglobulins and electrophoresis (? Paraprotein)
CT chest, abdo, pelvis - ? Evidence of lymphadenopathy / splenomegaly

Management of acquired angioedema:
Supportive (airway)
Androgens 
Antifibrinolytics
C1 Inhibitor concentrate (may need more)
Icatibant
Less data for newer therapies / those in development
Immunosuppressive therapy
107
Q

What are the other causes of Hereditary Angioedema?

A

Other causes of angioedema

Allergic – often with hives, responds to antihistamines

Drug induced – often ACE inhibitors

Idiopathic / spontaneous

ACE induced angioedema
Life-threatening to minor swelling (may not report to health-care provider)
Can resolve spontaneously
Often unilateral
Often starts overnight

In severe cases:
Swelling of lips, tongue, post pharynx, eyes
Dyspnea, dysphagia, dysphonia in up to 20% patients  may cause airway obstruction

Idiopathic angioedema
Recurrent angioedema, no recognized exogenous precipitant, not associated with concomitant urticaria
Typically: episodes of swelling of lips, cheeks, eyes, tongue, pharynx, extremities, genitalia
Slower than allergy induced
May be worsened by infection
Try antihistamines, steroids acutely
Antihistamines & antifibrinolytics

108
Q

What does of Adrenaline is given in Anaphylaxis?When can a second dose be given?

A

< 6 months 150 micrograms (0.15ml 1 in 1,000)
6 months - 6 years 150 micrograms (0.15ml 1 in 1,000)
6-12 years 300 micrograms (0.3ml 1 in 1,000)
Adult and child > 12 years 500 micrograms (0.5ml 1 in 1,000)

In the treatment of anaphylaxis, you can repeat adrenaline every 5 minutes

Given intramuscularly usually to the anterolateral aspect of the middle third of the thigh

109
Q

When is skin prick and skin patch tests done?

A

Skin prick test

Most commonly used test as easy to perform and inexpensive. Drops of diluted allergen are placed on the skin after which the skin is pierced using a needle. A large number of allergens can be tested in one session. Normally includes a histamine (positive) and sterile water (negative) control. A wheal will typically develop if a patient has an allergy. Can be interpreted after 15 minutes
Useful for food allergies and also pollen

Radioallergosorbent test (RAST) Determines the amount of IgE that reacts specifically with suspected or known allergens, for example IgE to egg protein. Results are given in grades from 0 (negative) to 6 (strongly positive)

Useful for food allergies, inhaled allergens (e.g. Pollen) and wasp/bee venom
Blood tests may be used when skin prick tests are not suitable, for example if there is extensive eczema or if the patient is taking antihistamines

Skin patch testing

Skin patch testing Useful for contact dermatitis. Around 30-40 allergens are placed on the back. Irritants may also be tested for. The patches are removed 48 hours later with the results being read by a dermatologist after a further 48 hours

110
Q

In the emergency treatment of anaphylaxis which 3 drugs are used and stipulated in the Resus Council guidelines?

A

500 microgram Adrenaline,200mg hydrocortisone and 10mg chlorphenamine are medications used in anaphylaxis